title: [Role of splenectomy in the treatment of myelofibrosis].
abstract: OBJECTIVE
  To evaluate the clinical and hematologic efficiency of splenectomy (SE) in patients with myelofibrosis (MF) resistant to conventional traditional treatment.
  
  
  METHODS
  Case histories were retrospectively analyzed in 52 MF patients who had been followed up at the Hematology Research Center, Ministry of Health of the Russian Federation, in 2004 to 2012 and undergone therapeutic SE (47 patients with primary myelofibrosis, 4 with postpolycythemia myelofibrosis, and 1 with postthrombocythemia myelofibrosis). The mean age was 47 years at diagnosis and 53 years before surgery. The patients younger than 50 years of age constituted 60%. Massive and giant splenomegaly was detected in 37 (71%) patients. The spleen weighing 0.9 to 2.9 and 3 to 7 kg was removed in 15 (29%) and 35 (67%) patients, respectively. In 2 cases, the weight of the removed spleen was as much as 10 and 11 kg.
  
  
  RESULTS
  By the moment of SE, the disease duration averaged 76 (from 1 to 240) months. Twenty-one (40%) patients developed perioperative complications, including bleeding (15%), thrombosis (11.5%), and infectious complications (13.5%). There were no deaths from surgical interventions in the intra- and early postoperative periods. In more than 80% of the patients after SE, their general condition improved and the symptoms of intoxication disappeared; in the majority of patients, the therapeutic effect lasted about 2 years. In the follow-up period, 33 (63%) patients died; the time to death averaged 27 (1-84) months following SE. The causes of death were blast transformation in 27 (82%) patients and comorbidity in 6 (18%); 19 (37%) patients with an average post-SE follow-up of 37 (4-72) months continued hydroxyurea treatment. The median survival after SE was equal to 3 years; the median overall survival was 11 years.
  
  
  CONCLUSIONS
  SE is effective palliative care with an acceptable level of occurring complications for individual patients with MF. Contraindications to SE as blast crisis and severe comorbidities should be strictly taken into account.
authors.forename: A L
authors.initials: AL
authors.lastname: Melikian
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Kolosova
authors.forename: M A
authors.initials: MA
authors.lastname: Sokolova
authors.forename: A M
authors.initials: AM
authors.lastname: Kovrigina
authors.forename: M A
authors.initials: MA
authors.lastname: Silaev
authors.forename: E A
authors.initials: EA
authors.lastname: Giliazitdinova
authors.forename: É G
authors.initials: ÉG
authors.lastname: Gemdzhian
authors.forename: S R
authors.initials: SR
authors.lastname: Karagiulian
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007431:Intraoperative Complications; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011183:Postoperative Complications; D055728:Primary Myelofibrosis / Q000150:complications / Q000401:mortality / Q000601:surgery*; D012189:Retrospective Studies; D013156:Splenectomy / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D013163:Splenomegaly / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D016896:Treatment Outcome